Celltrion, Inc. Logo

Celltrion, Inc.

Biopharmaceutical firm developing biosimilars for autoimmune diseases and oncology.

068270 | KO

Overview

Corporate Details

ISIN(s):
KR7068270008
LEI:
Country:
South Korea
Address:
인천광역시 연수구 아카데미로 23, 인천광역시

Description

Celltrion, Inc. is a biopharmaceutical company that provides integrated solutions across the entire value chain, from research and development to clinical trials, regulatory affairs, and large-scale manufacturing. The company specializes in developing and producing innovative therapeutics, including biosimilars and novel biopharmaceuticals. Its portfolio primarily targets autoimmune diseases and oncology. Celltrion is recognized for launching the world's first monoclonal antibody biosimilar. A key product is ZYMFENTRA® (infliximab-dyyb), a subcutaneous formulation for the maintenance treatment of moderately-to-severely active Crohn's disease and ulcerative colitis. The company also develops and manufactures chemical pharmaceuticals.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.5 KB
2025-06-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB

Automate Your Workflow. Get a real-time feed of all Celltrion, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Celltrion, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Celltrion, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.